Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q16790

UPID:
CAH9_HUMAN

ALTERNATIVE NAMES:
Carbonate dehydratase IX; Carbonic anhydrase IX; Membrane antigen MN; P54/58N; Renal cell carcinoma-associated antigen G250; pMW1

ALTERNATIVE UPACC:
Q16790; Q5T4R1

BACKGROUND:
Carbonic anhydrase 9, with aliases such as Membrane antigen MN and pMW1, is essential for pH balance in cells, facilitating the conversion of carbon dioxide to bicarbonate. This enzyme's activity is critical for maintaining the physiological environment necessary for cellular functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Carbonic anhydrase 9 offers a pathway to innovative therapeutic approaches. Given its significant role in cellular pH regulation, targeting this enzyme could lead to the development of novel treatments for conditions where pH balance is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.